ArticleAAPS PharmSciTech2026
Design, Optimization, and In Vitro Evaluation of Lactoferrin-Coated Brexpiprazole-Loaded Nanostructured Lipid Carriers for Brain Targeting.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to develop lactoferrin-coated Brexpiprazole-loaded nanostructured lipid carriers (Lf-BXP-NLCs) using a Design of Experiments (DoE) approach combined with an artificial neural network (ANN) to improve brain targetability and prolong residence time.
methodDrug solubility and interactions of Brexpiprazole with solid lipid, liquid lipid, surfactant, and co-surfactant were evaluated using in silico molecular docking. NLCs were prepared by hot high-speed homogenization. Plackett-Burman design was employed to screen critical formulation and process variables, while the Box-Behnken design enabled optimization. A feed-forward ANN model was developed to predict particle size (PS) and drug release (DR), and to assist in selecting formulations meeting critical quality attributes (CQAs). NLCs were characterized for physicochemical properties, encapsulation efficiency, morphology, in vitro release, ex vivo studies, and stability.
resultsBrexpiprazole showed higher solubility in GMS, oleic acid, Tween®80, and Span®80, supported by favorable docking interactions (-1.6 to -2.0 kcal/mol). Liquid lipid content, homogenization speed, and sonication time significantly influenced PS and DR, with liquid lipid amount identified as the most critical factor. Optimized Lf-BXP-NLCs exhibited a PS of 132.8 ± 2.4 nm, PDI 0.249 ± 0.013, and zeta potential -26.2 ± 1.3 mV. High entrapment efficiency (87.8 ± 0.25%) and drug loading (11.71 ± 0.03%) were achieved, along with extended drug release (55.00 ± 2.26%-66.97 ± 2.25% at 12-24 h, 96.14 ± 2.96% at 28 h) and higher permeation flux (75.35 µg/cm
conclusionThe integrated DoE-Assessment of a predicted model-based successful optimization of lactoferrin-functionalized extended release Brexpiprazole-loaded NLCs with 132.8 ± 2.4 nm, and zeta potential -26.2 ± 1.3 mV, which demonstrated strong compatibility, sustained release, and promising potential for targeted nose-to-brain delivery of Brexpiprazole.
Indexed as
Identifiers
41872417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.